Decheng Capital LLC Boosts Holdings in Arcus Biosciences, Inc. $RCUS

Decheng Capital LLC lifted its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 242.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 547,609 shares of the company’s stock after purchasing an additional 387,609 shares during the period. Arcus Biosciences makes up 1.3% of Decheng Capital LLC’s holdings, making the stock its 11th biggest holding. Decheng Capital LLC’s holdings in Arcus Biosciences were worth $7,447,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in RCUS. AQR Capital Management LLC lifted its holdings in Arcus Biosciences by 253.9% during the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after buying an additional 65,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Arcus Biosciences by 10.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock valued at $297,000 after buying an additional 3,565 shares during the period. Millennium Management LLC grew its stake in shares of Arcus Biosciences by 29.2% in the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after acquiring an additional 270,253 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after acquiring an additional 470,755 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of Arcus Biosciences during the first quarter worth $67,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Stock Down 3.4%

Shares of NYSE:RCUS opened at $21.92 on Monday. The stock has a market cap of $2.75 billion, a P/E ratio of -6.64 and a beta of 0.85. The firm has a fifty day moving average price of $21.51 and a 200 day moving average price of $19.46. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.36 and a quick ratio of 4.36. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.22. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. The business had revenue of $33.00 million during the quarter, compared to analysts’ expectations of $24.94 million. During the same period in the prior year, the company earned ($1.03) earnings per share. The business’s revenue was down 8.3% compared to the same quarter last year. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on RCUS shares. Truist Financial set a $30.00 price objective on Arcus Biosciences in a research note on Friday, December 12th. Wells Fargo & Company set a $23.00 target price on Arcus Biosciences and gave the stock an “equal weight” rating in a research note on Thursday, February 12th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Arcus Biosciences in a report on Monday, March 2nd. Bank of America increased their price target on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Finally, UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.20.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 31,823 shares of Arcus Biosciences stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.41, for a total value of $681,330.43. Following the transaction, the president directly owned 922,240 shares in the company, valued at approximately $19,745,158.40. This trade represents a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Carolyn C. Tang sold 7,658 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $167,557.04. Following the completion of the transaction, the general counsel directly owned 131,544 shares in the company, valued at approximately $2,878,182.72. The trade was a 5.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 180,990 shares of company stock worth $3,974,764 over the last three months. 9.60% of the stock is currently owned by company insiders.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.